Johnson & Johnson Return on Tangible Equity 2010-2022 | JNJ

Current and historical return on tangible equity values for Johnson & Johnson (JNJ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Johnson & Johnson Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-06-30 $18.37B $-0.22B -287.52%
2022-03-31 $19.83B $-4.65B -189.68%
2021-12-31 $20.88B $-7.62B -143.65%
2021-09-30 $17.88B $-13.07B -92.84%
2021-06-30 $17.77B $-16.48B -87.95%
2021-03-31 $15.12B $-20.96B -73.16%
2020-12-31 $14.71B $-26.52B -72.49%
2020-09-30 $16.99B $-16.84B -88.83%
2020-06-30 $15.19B $-18.33B -73.55%
2020-03-31 $17.17B $-19.52B -79.42%
2019-12-31 $15.12B $-21.81B -70.04%
2019-09-30 $14.15B $-22.93B -68.33%
2019-06-30 $16.33B $-22.21B -87.54%
2019-03-31 $14.68B $-19.39B -83.96%
2018-12-31 $15.30B $-18.31B -86.43%
2018-09-30 $1.54B $-14.71B -7.96%
2018-06-30 $1.37B $-17.51B -7.35%
2018-03-31 $1.25B $-20.26B -6.98%
2017-12-31 $1.30B $-24.97B -14.82%
2017-09-30 $15.83B $-11.90B 596.35%
2017-06-30 $16.34B $-14.25B 146.93%
2017-03-31 $16.51B $16.03B 79.16%
2016-12-31 $16.54B $20.74B 71.66%
2016-09-30 $15.94B $21.96B 66.88%
2016-06-30 $15.03B $24.68B 61.54%
2016-03-31 $15.55B $24.96B 65.03%
2015-12-31 $15.41B $23.76B 68.35%
2015-09-30 $14.72B $24.29B 67.57%
2015-06-30 $16.11B $22.62B 70.43%
2015-03-31 $15.92B $19.51B 65.10%
2014-12-31 $16.32B $20.70B 62.16%
2014-09-30 $17.32B $28.65B 64.36%
2014-06-30 $15.55B $28.94B 63.82%
2014-03-31 $15.06B $26.76B 68.32%
2013-12-31 $13.83B $23.31B 71.01%
2013-09-30 $12.88B $18.49B 75.47%
2013-06-30 $12.87B $19.62B 81.73%
2013-03-31 $10.44B $16.50B 78.55%
2012-12-31 $10.85B $13.65B 68.33%
2012-09-30 $8.50B $13.19B 46.80%
2012-06-30 $8.74B $9.82B 40.29%
2012-03-31 $10.11B $26.87B 38.71%
2011-12-31 $9.67B $22.80B 37.70%
2011-09-30 $11.40B $27.25B 43.67%
2011-06-30 $11.61B $27.51B 45.54%
2011-03-31 $12.28B $25.05B 51.06%
2010-12-31 $13.33B $24.57B 57.77%
2010-09-30 $13.60B $24.85B 62.41%
2010-06-30 $13.53B $21.76B 66.77%
2010-03-31 $13.29B $21.14B 69.33%
2009-12-31 $12.27B $19.40B 69.72%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $435.655B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17